Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK1809 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 A-1 | EXPERIMENTAL | Part 1; Panel A; Sequence 1: 2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan |
| Part 1 A-2 | EXPERIMENTAL | Part 1; Panel A; Sequence 2: Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809 |
| Part 1 A-3 | EXPERIMENTAL | Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809 |
| Part 1 A-4 | EXPERIMENTAL | Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo |
| Part 1 A-5 | EXPERIMENTAL | Part 1; Panel A; Sequence 5: Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809 |
| Part 1 B-1 | EXPERIMENTAL | Part 1; Panel B; Sequence 1: 5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food |
| Part 1 B-2 | EXPERIMENTAL | Part 1; Panel B; Sequence 2: 5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food |
| Part 1 B-3 | EXPERIMENTAL | Part 1; Panel B; Sequence 3: 5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food |
| Part 1 B-4 | EXPERIMENTAL | Part 1; Panel B; Sequence 4: Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food |
| Part 1 B-5 | EXPERIMENTAL | Part 1; Panel B; Sequence 5: Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food |
| Part 2 C-1 | EXPERIMENTAL | Part 2; Panel C; Sequence 1: 50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan |
| Part 2 C-2 | EXPERIMENTAL | Part 2; Panel C; Sequence 2: 50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809 |
| Part 2 C-3 | EXPERIMENTAL | Part 2; Panel C; Sequence 3: Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo |
| Part 2 C-4 | EXPERIMENTAL | Part 2; Panel C; Sequence 4: 50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809 |
| Part 2 C-5 | EXPERIMENTAL | Part 2; Panel C; Sequence 5: Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809 |
| Name | Type | Description |
|---|---|---|
| MK1809 | DRUG | single oral doses of MK1809 |
| Comparator: Losartan | DRUG | single oral doses of 100 mg Losartan |
| Comparator: Placebo | DRUG | Placebo to MK1809 |
Inclusion Criteria: Part 1: * Nonsmoker for at least 6 months * Body Mass Index (BMI) less than or equal to 29 kg/m2 * In overall good health Part 2: * Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2 * In overall good health (patients with hypertension and/or hyperli...
MK1809 is an investigational small molecule being developed for the treatment of hypertension, a cardiovascular condition characterized by elevated blood pressure. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MK1809 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical development for hypertension.
MK1809 is in Phase 1 clinical development. It is an investigational drug for hypertension and has not been approved by the FDA or any other regulatory agency. The drug is still in the early stages of clinical testing.
MK1809 has one completed Phase 1 clinical trial, registered as NCT01033318, which studied the pharmacokinetics and pharmacodynamics of the drug in 30 participants with hypertension. The trial was randomized, double-blind, and controlled, and included healthy volunteers.
No, MK1809 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for hypertension. The drug has completed one Phase 1 trial, but it remains in clinical development and has not received regulatory approval.